Would you offer adjuvant immunotherapy after salvage neck dissection for persistent nodal disease after definitive chemoRT for a patient with p16+ oropharyngeal SCC?

I am assuming that this HPV+ oropharyngeal cancer patient was treated with definitive CRT and then on a 3-month follow-up, PET had persistent nodal disease, which was definitively treated with a neck dissection. If the pathology revealed positive disease, then I would not offer the patient further therapy. We have no data, to date, to support the use of adjuvant immunotherapy in patients with p16+ tumors who have failed definitive therapy. With this said, data from the University of Pittsburgh, presented at ASCO in 2022, in a randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally ad...